The Program Cost and Cost-Effectiveness of Screening Men for Chlamydia to Prevent Pelvic Inflammatory Disease in Women
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Because men transmit Chlamydia trachomatis to women, screening men to prevent pelvic inflammatory disease in women may be a viable strategy. However, the cost-effectiveness of this approach requires careful assessment. METHODS: Data from a demonstration project and longitudinal study that examined screening men for chlamydia were applied to a compartment-based transmission model to estimate the cost-effectiveness of screening men for chlamydia compared with alternative interventions, including expanded screening of women and combining disease investigation specialist-provided partner notification with screening. Cases of pelvic inflammatory disease and quality-adjusted life years lost were the primary outcome measures. A male screening program that screened 1% of men in the population annually was modeled. RESULTS: A program targeting high-risk men for screening (those with a larger number of partners in the previous year than the general population and a higher chlamydia prevalence) was cost saving compared with using equivalent program dollars to expand screening of lower-risk women. Combining partner notification with male screening was more effective than screening men alone. In sensitivity analyses, the male program was not always cost saving but averaged $10,520 per quality-adjusted life year saved over expanded screening of women. CONCLUSIONS: Screening men can be a cost-effective alternative to screening women, but the men screened must have a relatively high prevalence compared with the women to whom screening would be expanded (under baseline assumptions, the prevalence in screened men was 86% higher than that of screened women). These modeling results suggest that programs targeting venues that have access to high-risk men can be effective tools in chlamydia prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1993 Sexually Transmitted Diseases Treatment Guidelines
(1994) · Journal of School Health · doi:10.1111/j.1746-1561.1994.tb03287.x · Cited by 918
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998) · Medical Care · doi:10.1097/00005650-199806000-00002 · Cited by 357
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Gift, T. L., Kissinger, P., Mohammed, H., Leichliter, J. S., Hogben, M., & Golden, M. R. (2011) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e31822e9192 · Cited by 47
Self-citationCost-effectiveness of opt-out chlamydia testing for high-risk young women in the U.S.
Owusu-Edusei, K., Hoover, K. W., & Gift, T. L. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.01.007 · Cited by 31
Self-citationWorld Health Organization (2024) · doi:10.2471/b09099 · Cited by 1
Metadata
- Authors
- Gift, T. L., Gaydos, C. A., Kent, C. K., Marrazzo, J. M., Rietmeijer, C. A., Schillinger, J. A., & Dunne, E. F.
- Venue
- Sexually Transmitted Diseases
- Published
- 2008-11
- Volume
- 35
- Issue
- 11
- Pages
- S66-S75
- ISSN
- 0148-5717 (ISSN-L)
- OpenAlex
- W2039465520
- Cited by
- 60
- References
- 2
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.